StreetInsider.com News Articles

Imunon to present IMNN-001 ovarian cancer data at AACR conference

Thu, 23 Jul 2026 09:25:28 -0400

Imunon, Inc. (Nasdaq: IMNN) announced that new data on its IMNN-001 immunotherapy candidate for advanced ovarian cancer will be featured in a poster presentation at the inaugural American Association for Cancer Research Conference on Drug Discovery and Development (AACR D3), held July 21-24, 2026 in Boston, Massachusetts.

The presentation covers translational and clinical data from Imunon's Phase 2 OVATION-2 study, a randomized, controlled trial in 112 patients with newly diagnosed advanced ovarian cancer. The poster reports that IMNN-001 combined with neoadjuvant/adjuvant chemotherapy was associated with a numerical increase in median overall survival of more than 13 months compared to chemotherapy alone

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

Thu, 23 Jul 2026 09:25:00 -0400

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism

First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development

LAWRENCEVILLE, N.J., July 23, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that new data on IMNN-001, the Company's DNA-based interleukin-12 (IL-12) immunotherapy for advanced ovarian cancer, will be featured in a poster presentation at the inaugural AACR Conference on Drug Discovery and Development

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

Thu, 23 Jul 2026 09:25:00 -0400

Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism

First-of-its-kind meeting spotlights IMNN-001 as one of the novel technologies shaping the future of cancer drug discovery and development

Form 4 Imunon, Inc. For: Jul 17 Filed by: Tardugno Michael H

Tue, 21 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260721/26795875.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Tardugno Michael H

Tue, 21 Jul 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260721/26795875.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Eylward Susan

Tue, 21 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260721/26795857.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Eylward Susan

Tue, 21 Jul 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260721/26795857.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Faller Douglas Vincent

Tue, 21 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260721/26795828.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Faller Douglas Vincent

Tue, 21 Jul 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260721/26795828.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Lindborg Stacy

Tue, 21 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260721/26795777.html

Form 4 Imunon, Inc. For: Jul 17 Filed by: Lindborg Stacy

Tue, 21 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260721/26795777.html

Imunon reports Phase 2 MRD data for IMNN-001 in ovarian cancer

Tue, 21 Jul 2026 09:00:28 -0400

Imunon, Inc. (Nasdaq: IMNN) announced preliminary data from its ongoing Phase 2 minimal residual disease (MRD) translational clinical trial of IMNN-001, an IL-12 DNA-based immunotherapy being evaluated in women with newly diagnosed advanced ovarian cancer.

The study, conducted in partnership with Break Through Cancer through its Targeting Minimal Residual Disease in Ovarian Cancer TeamLab, is led by investigators at The University of Texas MD Anderson Cancer Center. Nine patients in each arm have reached second-look laparoscopy, the primary assessment point for surgical MRD, out of a total target accrual of 30 patients.

Preliminary results showed a lower MRD-positive rate in patients treated

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Tue, 21 Jul 2026 09:00:00 -0400

Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial

Lower rate of minimal residual disease (MRD)
Higher ctDNA clearance with IMNN-001 vs. control
Highly favorable safety and tolerability profile

Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism of remodeling the tumor immune microenvironment

LAWRENCEVILLE, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced new

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

Tue, 21 Jul 2026 09:00:00 -0400

Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial

Lower rate of minimal residual disease (MRD)
Higher ctDNA clearance with IMNN-001 vs. control
Highly favorable safety and tolerability profile

Study, conducted in partnership with Break Through Cancer, provides new translational data and further support for IMNN-001's unique mechanism of remodeling the tumor immune microenvironment

LAWRENCEVILLE, N.J., July 21, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced new

Form 4 Imunon, Inc. For: Jul 02 Filed by: Tardugno Michael H

Tue, 07 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26742596.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Tardugno Michael H

Tue, 07 Jul 2026 17:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26742596.html

Form 3 Imunon, Inc. For: Jul 01 Filed by: Blacher Joshua

Tue, 07 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26742551.html

Form 3 Imunon, Inc. For: Jul 01 Filed by: Blacher Joshua

Tue, 07 Jul 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260707/26742551.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Eylward Susan

Tue, 07 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260707/26742510.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Eylward Susan

Tue, 07 Jul 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260707/26742510.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Faller Douglas Vincent

Tue, 07 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260707/26742495.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Faller Douglas Vincent

Tue, 07 Jul 2026 16:57:00 -0400

si-local-file:///var/storage/secattach/20260707/26742495.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Lindborg Stacy

Tue, 07 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260707/26742485.html

Form 4 Imunon, Inc. For: Jul 02 Filed by: Lindborg Stacy

Tue, 07 Jul 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260707/26742485.html

Imunon names new interim CFO as predecessor retires

Tue, 30 Jun 2026 16:40:36 -0400

Imunon, Inc. (NASDAQ: IMNN) announced that Jeffrey Church, who has served as interim Chief Financial Officer since January 2026, informed the company of his intent to retire from the position effective July 1, 2026.

To assist with the transition, Church and the company agreed he would continue in a consulting role. Under an amended consulting agreement effective July 1, 2026, Imunon will pay Church a monthly retainer of $10,000, terminable upon two business days' notice. The company stated his departure is due to retirement and involves no disagreements with management.

Effective July 1, 2026, Imunon appointed Josh Blacher as the new interim